Summit Therapeutics Inc. - 8-K Filing
Summit Therapeutics stockholders approve amendment to increase authorized common stock by 1 billion shares and reports Q3 2026 financial results. (Items: 2.02 as if fully set forth herein, 5.07 below, on November 4, 2026, the Company held its Special Meeting of Stockholders (the “Special Meeting”), at which the Company’s stockholders)
Tickers: $SMMT